Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Developing whole cell standards for the microbiome field.
Sergaki C, Anwar S, Fritzsche M, Mate R, Francis RJ, MacLellan-Gibson K, Logan A, Amos GCA. Sergaki C, et al. Among authors: francis rj. Microbiome. 2022 Aug 9;10(1):123. doi: 10.1186/s40168-022-01313-z. Microbiome. 2022. PMID: 35945640 Free PMC article.
Intrinsic host susceptibility among multiple species to intranasal SARS-CoV-2 identifies diverse virological, biodistribution and pathological outcomes.
Berry N, Ferguson D, Kempster S, Hall J, Ham C, Jenkins A, Rannow V, Giles E, Leahy R, Goulding S, Fernandez A, Adedeji Y, Vessillier S, Rajagopal D, Prior S, Le Duff Y, Hurley M, Gilbert S, Fritzsche M, Mate R, Rose N, Francis RJ, MacLellan-Gibson K, Suarez-Bonnet A, Priestnall S, Almond N. Berry N, et al. Among authors: francis rj. Sci Rep. 2022 Nov 4;12(1):18694. doi: 10.1038/s41598-022-23339-x. Sci Rep. 2022. PMID: 36333445 Free PMC article.
Human iPSC-Derived Neural Crest Stem Cells Exhibit Low Immunogenicity.
Mehler VJ, Burns CJ, Stauss H, Francis RJ, Moore ML. Mehler VJ, et al. Among authors: francis rj. Mol Ther Methods Clin Dev. 2020 Jan 13;16:161-171. doi: 10.1016/j.omtm.2019.12.015. eCollection 2020 Mar 13. Mol Ther Methods Clin Dev. 2020. PMID: 32055644 Free PMC article.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Gedye C, Rutherford NK, Sandhu S, Kumar AR, Pook D, Ramdave S, Nadebaum DP, Voskoboynik M, Redfern AD, Macdonald W, Krieger L, Schembri G, Chua W, Lin P, Horvath L, Bastick P, Butler P, Zhang AY, Yip S, Thomas H, Langford A, Hofman MS, McJannett M, Martin AJ, Stockler MR, Davis ID; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: francis rj. Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12. Lancet Oncol. 2024. PMID: 38621400 Clinical Trial.
133 results